280 related articles for article (PubMed ID: 36198246)
41. Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.
Efuni E; Cytryn S; Boland P; Niewold TB; Pavlick A; Weber J; Sandigursky S
J Clin Rheumatol; 2021 Oct; 27(7):267-271. PubMed ID: 31977647
[TBL] [Abstract][Full Text] [Related]
42. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
43. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
44. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
45. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
Front Oncol; 2021; 11():749064. PubMed ID: 34900695
[TBL] [Abstract][Full Text] [Related]
46. Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study.
Gérard AO; Barbosa S; Parassol N; Andreani M; Merino D; Cremoni M; Laurain A; Pinel S; Bourneau-Martin D; Rocher F; Esnault VLM; Borchiellini D; Sicard A; Drici MD;
Clin Kidney J; 2022 Oct; 15(10):1881-1887. PubMed ID: 36158153
[TBL] [Abstract][Full Text] [Related]
47. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
Noseda R; Bertoli R; Müller L; Ceschi A
J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
49. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report.
Pesola G; Murianni V; Rebuzzi SE; Banna GL; Cerbone L; Catalano F; Borea R; Gandini A; Cremante M; Puglisi S; Trovato F; Fornarini G
Immunotherapy; 2021 Dec; 13(17):1379-1386. PubMed ID: 34743545
[TBL] [Abstract][Full Text] [Related]
50. Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy.
Wang H; Zhou F; Zhao C; Cheng L; Zhou C; Qiao M; Li X; Chen X
Front Immunol; 2022; 13():840313. PubMed ID: 35222434
[TBL] [Abstract][Full Text] [Related]
51. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
52. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system.
Yan YD; Zhao Y; Zhang C; Fu J; Su YJ; Cui XL; Ma EL; Liu BL; Gu ZC; Lin HW
EClinicalMedicine; 2022 Aug; 50():101535. PubMed ID: 35812997
[TBL] [Abstract][Full Text] [Related]
53. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.
Feng S; Coward J; McCaffrey E; Coucher J; Kalokerinos P; O'Byrne K
J Thorac Oncol; 2017 Nov; 12(11):1626-1635. PubMed ID: 28843363
[TBL] [Abstract][Full Text] [Related]
54. Pharmacist's role in immune-related adverse events management: real-world incidence and risk evaluation from immunotherapy.
Meanwatthana J; Chantarasap P; Chuatrisorn I; Wiriya T; Jitawatanarat P
Int J Pharm Pract; 2022 Aug; 30(4):377-382. PubMed ID: 35731644
[TBL] [Abstract][Full Text] [Related]
55. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
56. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy.
Ohnuma K; Hatano R; Dang NH; Morimoto C
Mod Rheumatol; 2019 Sep; 29(5):721-732. PubMed ID: 30285531
[TBL] [Abstract][Full Text] [Related]
57. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
58. Management of autoimmune and viral hepatitis in immunotherapy: a narrative review.
Kuo L; Kuwelker S; Tsai E
Ann Palliat Med; 2023 Nov; 12(6):1275-1294. PubMed ID: 37731304
[TBL] [Abstract][Full Text] [Related]
59. Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes.
Bruyère CL; Souquet PJ; Dalle S; Corbaux P; Boespflug A; Duruisseaux M; Kiakouama-Maleka L; Reverdy T; Maugeais M; Sahin G; Maillet D; Péron J
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34068892
[TBL] [Abstract][Full Text] [Related]
60. Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study.
Reid P; Liew DF; Akruwala R; Bass AR; Chan KK
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34526389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
